Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunoreactive endothelin in pheochromocytomas.

M Sone1, K Totsune, K Takahashi

  • 1Second Department of Internal Medicine, Tohoku University School of Medicine, Japan.

Journal of Cardiovascular Pharmacology
|January 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The brainstem noradrenergic systems in stress, anxiety and depression.

Journal of neuroendocrinology·2010
Same author

Blockade of tachykinin NK1/NK2 receptors in the brain attenuates the activation of corticotrophin-releasing hormone neurones in the hypothalamic paraventricular nucleus and the sympathoadrenal and pituitary-adrenal responses to formalin-induced pain in the rat.

Journal of neuroendocrinology·2010
Same author

Participation of the prolactin-releasing peptide-containing neurones in caudal medulla in conveying haemorrhagic stress-induced signals to the paraventricular nucleus of the hypothalamus.

Journal of neuroendocrinology·2009
Same author

Glucocorticoid dependency of surgical stress-induced FosB/DeltaFosB expression in the paraventricular and supraoptic nuclei of the rat hypothalamus.

Journal of neuroendocrinology·2009
Same author

Prolactin-releasing peptide regulates the cardiovascular system via corticotrophin-releasing hormone.

Journal of neuroendocrinology·2009
Same author

Suprachoroidal fluid as a complication of 23-gauge vitreous surgery.

The British journal of ophthalmology·2008
Same journal

Integration of Mendelian Randomization and FAERS Database Analysis Reveals the Association Between Ergotamine and Aortic and Mitral Valve Diseases.

Journal of cardiovascular pharmacology·2026
Same journal

A Comprehensive Review of PCSK9 Inhibitor Therapy.

Journal of cardiovascular pharmacology·2026
Same journal

SGLT2 Inhibitors and Progression of Chronic Kidney Disease in Patients with Elevated Lipoprotein(a): A Real-World Cohort Study.

Journal of cardiovascular pharmacology·2026
Same journal

Aspirin in primary prevention: a case for selective use.

Journal of cardiovascular pharmacology·2026
Same journal

GLP-1 Gene Therapy Trial for Obesity and Type 2 Diabetes: Towards a New Paradigm for Chronic Disease Treatment.

Journal of cardiovascular pharmacology·2026
Same journal

Expert Opinion: Restrictions, Precautions, or Normalcy? Defining Everyday Risk in Patients Treated With IL-1 Blockers for Recurrent Pericarditis.

Journal of cardiovascular pharmacology·2026
See all related articles

Endothelin (ET) is present in pheochromocytoma tumor tissues, with elevated levels found in half of the patients studied. This study investigated endothelin

Area of Science:

  • Endocrinology
  • Oncology
  • Biochemistry

Background:

  • Pheochromocytoma is a neuroendocrine tumor derived from chromaffin cells.
  • Endothelin (ET) is a potent vasoconstrictor peptide with potential roles in tumor growth and progression.

Purpose of the Study:

  • To investigate the presence and concentration of endothelin (ET) in pheochromocytoma tumor tissues and plasma.
  • To compare ET levels in pheochromocytoma patients with those in patients with primary aldosteronism, normal adrenal glands, essential hypertension, and healthy subjects.

Main Methods:

  • Radioimmunoassay (RIA) was used to quantify immunoreactive (ir-) ET concentrations in tumor tissues and plasma.
  • Sephadex G-50 column chromatography and reverse-phase high-performance liquid chromatography (RP-HPLC) were employed for ET characterization in tumor extracts.

Related Experiment Videos

Main Results:

  • Immunoreactive (ir-) ET concentrations in 12 pheochromocytomas ranged from 66 to 253 fmol/gwt, with a mean of 146 +/- 20 fmol/gwt.
  • Six out of 12 pheochromocytoma tumor tissues exhibited ir-ET concentrations higher than the upper limit observed in control tissues (primary aldosteronism and normal adrenal glands).
  • Chromatographic analysis confirmed the presence of a major peak eluting identically to synthetic ET-1 in pheochromocytoma tumor extracts.
  • Plasma ir-ET concentrations in pheochromocytoma patients were not significantly different from those in essential hypertension patients and normal subjects.

Conclusions:

  • High concentrations of endothelin-1 (ET-1) are present in the tumor tissues of approximately 50% of pheochromocytoma patients.
  • While plasma ET levels did not differ significantly, tissue analysis suggests a potential role for ET-1 in a subset of pheochromocytomas.